Benzinga  May 17  Comment 
Shares of Eli Lilly and Co (NYSE: LLY) have lost almost 10 percent since the beginning of the year. However, they have managed to recuperate almost 10 percent since their mid-March lows. Related Link: Here's How Crowdsourced Ratings Can Beat...
FiercePharma  May 11  Comment 
FDA warns of potentially fatal skin reactions to Lilly's Zyprexa ewasserman Wed, 05/11/2016 - 08:45
MedPage Today  May 10  Comment 
(MedPage Today) -- Zyprexa and Symbyax among products to get warning label
FierceBiotech  May 5  Comment 
FDA grants Eli Lilly a priority review for soft tissue sarcoma drug badams Thu, 05/05/2016 - 06:24
newratings.com  May 4  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced the U.S. FDA has granted Priority Review for the biologics license application for olaratumab, a PDGFR? antagonist, in combination with doxorubicin, for the potential treatment of...
Forbes  May 2  Comment 
Eli Lilly and Company (LLY) has declared a dividend for the second quarter of 2016 of $0.51 per share on outstanding common stock. The dividend is payable June 10, 2016, to shareholders of record at the close of business on May 13, 2016.
TheStreet.com  May 2  Comment 
The healthcare sector has looked unhealthy compared with the broader stock market after the first four months of 2016. The sector is down 3.1% compared with an S&P 500 up just 1%. As 2016 began, TheStreet's Jim Cramer named 38 stocks he...
GenEng News  Apr 27  Comment 
Adimab said today it has launched a research collaboration with Kodiak Sciences—while Eli Lilly, Jounce Therapeutics, and Kite Pharma have agreed to license antibody programs developed under existing partnerships. The value of the...
Wall Street Journal  Apr 26  Comment 
Lilly said revenue rose in its latest quarter as sales of new drugs helped offset declines in some established products.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki